Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis

Increase in regulatory T cells correlates with clinical response

Jun Kikuchi, Misato Hashizume, Yuko Kaneko, Keiko Yoshimoto, Naoshi Nishina, Tsutomu Takeuchi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, is clinically effective against rheumatoid arthritis (RA), and several reports have indicated how TCZ influences a number of mechanisms underlying RA pathogenesis. However, it is still unclear whether TCZ affects inflammatory cells in peripheral blood and whether any such changes are associated with clinical response. We evaluated associations between proportions of subsets of peripheral immune cells and clinical response in patients with RA treated with TCZ. Methods: Thirty-nine consecutive patients with RA who started to receive TCZ as their first biologic between March 2010 and April 2012 were enrolled. The proportions of several subsets of peripheral cells with their levels of expression of differentiation markers, activation markers and costimulatory molecules were measured sequentially from baseline to week 52 by flow cytometry analysis. Results: Clinical Disease Activity Index (CDAI) remission was achieved in 53.8% of patients at week 52 of TCZ therapy. The proportions of CD4+CD25+CD127low regulatory T cells (Treg) and HLA-DR+ activated Treg cells significantly increased with TCZ therapy (P<0.001 and P<0.001, respectively), whereas proportions of CD3+CD4+CXCR3-CCR6+CD161+ T helper 17 cells did not change over the 52weeks. The proportions of CD20+CD27+ memory B cells, HLA-DR+CD14+ and CD69+CD14+ activated monocytes, and CD16+CD14+ monocytes significantly decreased (P<0.001, P<0.001, P<0.001 and P<0.001, respectively). Among them, only the change in Treg cells was inversely correlated with the change in CDAI score (ρ=-0.40, P=0.011). The most dynamic increase in Treg cells was observed in the CDAI remission group (P<0.001). Conclusion: This study demonstrates that TCZ affected proportions of circulating immune cells in patients with RA. The proportion of Treg cells among CD4+ cells correlated well with clinical response.

Original languageEnglish
Article number10
JournalArthritis Research and Therapy
Volume17
Issue number1
DOIs
Publication statusPublished - 2015 Jan 21

Fingerprint

Regulatory T-Lymphocytes
Rheumatoid Arthritis
HLA-DR Antigens
Therapeutics
Monocytes
Interleukin-6 Receptors
Th17 Cells
tocilizumab
Differentiation Antigens
Flow Cytometry
B-Lymphocytes
Antibodies

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

@article{59d324a7a60b4df4bc55ff117bcc1e63,
title = "Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response",
abstract = "Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, is clinically effective against rheumatoid arthritis (RA), and several reports have indicated how TCZ influences a number of mechanisms underlying RA pathogenesis. However, it is still unclear whether TCZ affects inflammatory cells in peripheral blood and whether any such changes are associated with clinical response. We evaluated associations between proportions of subsets of peripheral immune cells and clinical response in patients with RA treated with TCZ. Methods: Thirty-nine consecutive patients with RA who started to receive TCZ as their first biologic between March 2010 and April 2012 were enrolled. The proportions of several subsets of peripheral cells with their levels of expression of differentiation markers, activation markers and costimulatory molecules were measured sequentially from baseline to week 52 by flow cytometry analysis. Results: Clinical Disease Activity Index (CDAI) remission was achieved in 53.8{\%} of patients at week 52 of TCZ therapy. The proportions of CD4+CD25+CD127low regulatory T cells (Treg) and HLA-DR+ activated Treg cells significantly increased with TCZ therapy (P<0.001 and P<0.001, respectively), whereas proportions of CD3+CD4+CXCR3-CCR6+CD161+ T helper 17 cells did not change over the 52weeks. The proportions of CD20+CD27+ memory B cells, HLA-DR+CD14+ and CD69+CD14+ activated monocytes, and CD16+CD14+ monocytes significantly decreased (P<0.001, P<0.001, P<0.001 and P<0.001, respectively). Among them, only the change in Treg cells was inversely correlated with the change in CDAI score (ρ=-0.40, P=0.011). The most dynamic increase in Treg cells was observed in the CDAI remission group (P<0.001). Conclusion: This study demonstrates that TCZ affected proportions of circulating immune cells in patients with RA. The proportion of Treg cells among CD4+ cells correlated well with clinical response.",
author = "Jun Kikuchi and Misato Hashizume and Yuko Kaneko and Keiko Yoshimoto and Naoshi Nishina and Tsutomu Takeuchi",
year = "2015",
month = "1",
day = "21",
doi = "10.1186/s13075-015-0526-4",
language = "English",
volume = "17",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis

T2 - Increase in regulatory T cells correlates with clinical response

AU - Kikuchi, Jun

AU - Hashizume, Misato

AU - Kaneko, Yuko

AU - Yoshimoto, Keiko

AU - Nishina, Naoshi

AU - Takeuchi, Tsutomu

PY - 2015/1/21

Y1 - 2015/1/21

N2 - Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, is clinically effective against rheumatoid arthritis (RA), and several reports have indicated how TCZ influences a number of mechanisms underlying RA pathogenesis. However, it is still unclear whether TCZ affects inflammatory cells in peripheral blood and whether any such changes are associated with clinical response. We evaluated associations between proportions of subsets of peripheral immune cells and clinical response in patients with RA treated with TCZ. Methods: Thirty-nine consecutive patients with RA who started to receive TCZ as their first biologic between March 2010 and April 2012 were enrolled. The proportions of several subsets of peripheral cells with their levels of expression of differentiation markers, activation markers and costimulatory molecules were measured sequentially from baseline to week 52 by flow cytometry analysis. Results: Clinical Disease Activity Index (CDAI) remission was achieved in 53.8% of patients at week 52 of TCZ therapy. The proportions of CD4+CD25+CD127low regulatory T cells (Treg) and HLA-DR+ activated Treg cells significantly increased with TCZ therapy (P<0.001 and P<0.001, respectively), whereas proportions of CD3+CD4+CXCR3-CCR6+CD161+ T helper 17 cells did not change over the 52weeks. The proportions of CD20+CD27+ memory B cells, HLA-DR+CD14+ and CD69+CD14+ activated monocytes, and CD16+CD14+ monocytes significantly decreased (P<0.001, P<0.001, P<0.001 and P<0.001, respectively). Among them, only the change in Treg cells was inversely correlated with the change in CDAI score (ρ=-0.40, P=0.011). The most dynamic increase in Treg cells was observed in the CDAI remission group (P<0.001). Conclusion: This study demonstrates that TCZ affected proportions of circulating immune cells in patients with RA. The proportion of Treg cells among CD4+ cells correlated well with clinical response.

AB - Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, is clinically effective against rheumatoid arthritis (RA), and several reports have indicated how TCZ influences a number of mechanisms underlying RA pathogenesis. However, it is still unclear whether TCZ affects inflammatory cells in peripheral blood and whether any such changes are associated with clinical response. We evaluated associations between proportions of subsets of peripheral immune cells and clinical response in patients with RA treated with TCZ. Methods: Thirty-nine consecutive patients with RA who started to receive TCZ as their first biologic between March 2010 and April 2012 were enrolled. The proportions of several subsets of peripheral cells with their levels of expression of differentiation markers, activation markers and costimulatory molecules were measured sequentially from baseline to week 52 by flow cytometry analysis. Results: Clinical Disease Activity Index (CDAI) remission was achieved in 53.8% of patients at week 52 of TCZ therapy. The proportions of CD4+CD25+CD127low regulatory T cells (Treg) and HLA-DR+ activated Treg cells significantly increased with TCZ therapy (P<0.001 and P<0.001, respectively), whereas proportions of CD3+CD4+CXCR3-CCR6+CD161+ T helper 17 cells did not change over the 52weeks. The proportions of CD20+CD27+ memory B cells, HLA-DR+CD14+ and CD69+CD14+ activated monocytes, and CD16+CD14+ monocytes significantly decreased (P<0.001, P<0.001, P<0.001 and P<0.001, respectively). Among them, only the change in Treg cells was inversely correlated with the change in CDAI score (ρ=-0.40, P=0.011). The most dynamic increase in Treg cells was observed in the CDAI remission group (P<0.001). Conclusion: This study demonstrates that TCZ affected proportions of circulating immune cells in patients with RA. The proportion of Treg cells among CD4+ cells correlated well with clinical response.

UR - http://www.scopus.com/inward/record.url?scp=84924324722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924324722&partnerID=8YFLogxK

U2 - 10.1186/s13075-015-0526-4

DO - 10.1186/s13075-015-0526-4

M3 - Article

VL - 17

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 10

ER -